- University of Illinois College of Medicine, Chicago – MD
- Oregon Health Science University, Portland, Oregon – Residency in Internal Medicine
- University of Wisconsin Hospital and Clinics and William S. Middleton Memorial Veterans Hospital – Fellowships in Medical Oncology and Geriatrics
Dr. Noelle LoConte is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine. She leads the UW Carbone Cancer Center’s Outreach, Cancer Control and Population Sciences division and its Data and Safety Monitoring Committee. She formerly served on the American Society of Clinical Oncology (ASCO) Prevention and Annual Meeting Scientific Program Committees.
Her many regional and national committee memberships include the Wisconsin Cancer Council Steering Committee; the Eastern Cooperative Oncology Group Gastrointestinal Cancer Core Committee; the National Comprehensive Cancer Network (NCCN) Treatment Guidelines Committee for Pancreatic Adenocarcinoma; the Big 10 Cancer Research Consortium Gastrointestinal Cancer Committee; and the ASCO Primary Care Provider Engagement Work Group, CancerLinq Discovery Research and Publications Committee, and Alcohol Policy Workgroup (the latter of which she chairs). She is also a reviewer for over a dozen medical journals, and has received a John A. Hartford Foundation/American Society of Clinical Oncology Foundation Young Investigator Award and a Wisconsin Cancer Council Certificate of Appreciation Award.
Dr. LoConte is one of the few physicians practicing in the Midwest with dual training in both medical oncology and geriatrics. Her clinical interests are in gastrointestinal cancers, as well as cancer of any type in the older adult.
View Dr. Noelle LoConte’s Publications on NCBI My Bibliography
Dr. LoConte’s research interests focus cancer prevention and control. She is the principal investigator on a Centers for Disease Control and Prevention-funded project that aims to increase colorectal cancer screening in Wisconsin, and has led many clinical trials of new chemotherapies for gastrointestinal cancers, from Phase I through Phase III studies.